DNLI 241220 15.00P (DNLI241220P15000) Stock Options, News & Quotes

US OptionsDetailed Quotes

DNLI241220P15000

Watchlist

0.05
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Denali Therapeutics Upgraded to Buy From Hold at Stifel
Yahoo FinanceDec 17 06:25 ET
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37
Moomoo NewsDec 16 07:31 ET · Ratings
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
BenzingaDec 16 06:58 ET · Ratings
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
BenzingaDec 6 13:03 ET
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Yahoo FinanceDec 6 11:31 ET
Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease
ReutersDec 5 08:00 ET

Comments

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Moomoo AI

Feb 7 06:59

Denali Therapeutics' continuous stock price drop questions the initial investment decision. The company's struggle to increase revenue while unprofitable worries investors. Despite a recent 3.9% rise, the company's disappointing performance over the past years resulted in a yearly 3% total loss for shareholders over five years.

Denali Therapeutics (NASDAQ:DNLI) Shareholders Are up 3.9% This Past Week, but Still in the Red Over the Last Three Years

MangoXoXo

Jan 30 18:16

$Denali Therapeutics (DNLI.US)$ 👀

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...